Major Events - Brain动极光-B (06681) signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center [1] - Cohere New Energy (00182) successfully completed a secondary listing on the Singapore Stock Exchange [1] - Bole康视云-B (02592) submitted a clinical trial application for the new drug CBT-009 to the Drug Evaluation Center [1] - Yingtong Holdings (06883) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its high-end fragrance distribution network in China [1] - Weimeng Group (02013) initiated a business cooperation with Taobao Flash Purchase [1] - Dali普控股 (01921) officially became a qualified supplier for Saudi Aramco [1] - Yiming Anke-B (01541) regained global rights for IMM2510 and IMM27M [1] - Yuexiu Property (00123) subsidiary Shanghai Yuheng won a land parcel in Shanghai's Pudong New District [1] Operating Performance - Jinxin Reproductive (01951) reported a further narrowing of the overall decline in IVF egg retrieval cycles to -1.4% for 2025 [1] - Poly Real Estate Group (00119) achieved a cumulative contract sales amount of approximately 50.2 billion yuan for 2025, a year-on-year decrease of 7.38% [1] - Yadea Holdings (01585) issued a profit warning, expecting annual net profit to be no less than 2.9 billion yuan [1] - Jindi Commercial Real Estate (00535) reported a cumulative contract sales total of approximately 10.696 billion yuan for 2025, a year-on-year decrease of 47.33% [1] - Greentown Management Holdings (09979) estimated the construction fee for newly developed projects in 2025 to be 9.35 billion yuan, a year-on-year increase of approximately 0.4% [1] - Sunac China (01918) achieved a cumulative contract sales amount of approximately 36.84 billion yuan for 2025, a year-on-year decrease of 21.85% [1]

Core Viewpoint - Concord New Energy Group Limited (CNE) has successfully completed its secondary listing on the Singapore Exchange (SGX), marking a significant milestone in its global business development strategy [1] Group 1: Company Overview - CNE is headquartered in Singapore and was originally listed on the Hong Kong Stock Exchange in 2007 [1] - The company focuses on providing high-quality clean energy and professional services, with operations in investment, development, and operation of wind, solar, and energy storage assets [1] - CNE currently has an operational capacity of over 5 GW [1] Group 2: Strategic Importance of Listing - The secondary listing on SGX is seen as a key step for CNE in enhancing its governance and integrating into the international capital market [1] - Singapore is positioned as a strategic hub for advanced artificial intelligence, next-generation energy systems, and global capital markets [1] Group 3: Market Impact - The listing highlights the role of global capital markets in promoting the scaling of renewable energy infrastructure and supporting the transition to sustainable energy [1] - SGX aims to provide an international platform for CNE to expand its diverse global network of investors, clients, and partners, thereby accelerating the clean energy transition [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 協合新能源集團有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00182 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | ...

Group 1 - The core viewpoint of the article is that Xiehe New Energy (00182.HK) successfully listed its shares on the new exchange through an introduction method [1] - The shares will trade under the code "SEG" on the main board of the new exchange with a trading unit of 100 shares per lot [1] - The shares will continue to be primarily listed and traded on the main board of the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, Xiehe New Energy, successfully listed its ordinary shares on the Singapore Exchange through an introduction method, with shares trading under the code "SEG" [1] Group 1 - The shares will be traded in board lots of 100 shares on the main board of the Singapore Exchange [1] - The shares remain primarily listed and traded on the main board of the Hong Kong Stock Exchange [1]

协合新能源(00182)公布，公司普通股今日以介绍方式成功于新交所上市。股份将以股份代码"SEG"于新 交所主板以每手100股股份的买卖单位买卖。股份仍主要于联交所主板上市及买卖。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司及新加坡證券交易所有限公司對本公 告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明不會就因本公告全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 - 1 - 本公司新加坡股份過戶代理之詳情如下： （新加坡股份代碼：SEG） 內幕消息 成功於新加坡證券交易所完成第二上市 本公告乃由Concord New Energy Group Limited（協合新能源集團有限公司*）（「本公司」）根據 香港聯合交易所有限公司（「聯交所」）證券上市規則第13.09(2)(a)條以及證券及期貨條例（香港 法例第571章）第XIVA部而作出。 茲提述本公司日期為二零二五年二月二十七日，內容有關建議於新交所主板第二上市之公 告、本公司日期為二零二五年十二月二十三日，內容有關接獲新交所之上市資格函之公告、 本公司日期為二零二五年十二月二十九日，內容有關介紹文件（「介紹文件」）之海外監管公 告，以及日期為二零二六年一月五日，內容有關建議第二上市之預計上市日期之公告（統稱 「該等公告」 ...

Major Events - Yunzhisheng (09678) secured a regional medical cooperation contract worth over 20 million [1] - Kelun-Biotech (06990) received breakthrough therapy designation from NMPA for TROP2 ADC drug in combination with pembrolizumab for treating PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] - InSilico Medicine (03696) entered into an 8.88 billion USD multi-year collaboration for anti-tumor drug development with Sihuiya [1] - Hutchison China MediTech (00013) is conducting a Phase III study on surufatinib combined with camrelizumab for first-line treatment of pancreatic ductal adenocarcinoma [1] - Ascletis Pharma-B (01672) announced FDA approval for IND of ASC30 in a 13-week Phase II study in diabetic patients [1] - Foryou Medical (01696) received quality standard inspection approval for its reauthorized injectable botulinum toxin from the Chinese National Medical Products Administration [1] - CanSino Biologics (06185) obtained clinical trial approval in China for its 24-valent pneumococcal polysaccharide conjugate vaccine [1] - Stone Group (02005) received drug production registration approval for perindopril and amlodipine tablets [1] - Sunny Optical Technology (02382) proposed to spin off its automotive optical business for independent listing on the Hong Kong Stock Exchange [1] - Dongyang Sunshine Pharmaceutical (06887) completed the first patient enrollment for HECN30227 in China [1] - Haitong International's subsidiary plans to sell 100% equity of Guohua Machinery for 342 million [1] - Yuexiu Property (00123) subsidiary intends to sell 73.74% actual equity in Hangzhou Yueyun [1] - CIMC Group (02039) subsidiary CIMC Shilianda plans to introduce strategic investors through capital increase and transfer of a small number of old shares [1] Operating Performance - Chifeng Jilong Gold Mining (06693) expects annual net profit attributable to shareholders to be approximately 3 billion to 3.2 billion, an increase of about 70% to 81% year-on-year [2] - Corning Hospital (02120) anticipates outpatient visits to reach approximately 720,200 in 2025, a year-on-year increase of 29% [2] - Seres (09927) reported total vehicle sales of 63,700 units in December, a year-on-year increase of 53.54% [2] - Xiehe New Energy (00182) reported an equity power generation of 790.32 GWh in December [2] - Country Garden (02007) reported contract sales amounting to approximately 2.69 billion attributable to shareholders in December [2]

本文源自：金融界AI电报 协合新能源(00182.HK)发布公告，该集团2025年12月权益发电量为790.32GWh。前12个月权益发电量为 8585.97GWh。 ...

協合新能源(00182)发布公告，该集团2025年12月权益发电量为790.32GWh。前12个月权益发电量为 8585.97GWh。 ...